Riccardo Perfetti - Jul 27, 2021 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)

Role
Chief Medical Officer
Signature
/s/ Shoshana Shendelman, Attorney-in-Fact
Stock symbol
APLT
Transactions as of
Jul 27, 2021
Transactions value $
-$713,606
Form type
4
Date filed
7/29/2021, 08:59 PM
Previous filing
Jul 15, 2021
Next filing
Aug 11, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLT Common Stock Options Exercise $21.6K +15K $1.44 15K Jul 27, 2021 Direct F1
transaction APLT Common Stock Sale -$133K -7.78K -51.84% $17.05* 7.22K Jul 27, 2021 Direct F2, F3
transaction APLT Common Stock Sale -$126K -7.22K -100% $17.39* 0 Jul 27, 2021 Direct F2, F4
transaction APLT Common Stock Options Exercise $21.6K +15K $1.44 15K Jul 28, 2021 Direct F1
transaction APLT Common Stock Sale -$263K -15K -100% $17.50* 0 Jul 28, 2021 Direct F2, F5
transaction APLT Common Stock Options Exercise $21.6K +15K $1.44 15K Jul 29, 2021 Direct F1
transaction APLT Common Stock Sale -$258K -15K -100% $17.18* 0 Jul 29, 2021 Direct F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLT Stock Option (Right to Buy) Options Exercise $0 -15K -9.16% $0.00 149K Jul 27, 2021 Common Stock 15K $1.44 Direct F1, F7
transaction APLT Stock Option (Right to Buy) Options Exercise $0 -15K -10.08% $0.00 134K Jul 28, 2021 Common Stock 15K $1.44 Direct F1, F7
transaction APLT Stock Option (Right to Buy) Options Exercise $0 -15K -11.22% $0.00 119K Jul 29, 2021 Common Stock 15K $1.44 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 Weighted average price. These shares were sold in multiple transactions at prices ranging from $16.2600 to $17.2500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 Weighted average price. These shares were sold in multiple transactions at prices ranging from $17.2600 to $17.7500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 Weighted average price. These shares were sold in multiple transactions at prices ranging from $16.9800 to $17.8450 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 Weighted average price. These shares were sold in multiple transactions at prices ranging from $17.0600 to $17.6250 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.